Alberta Investment Management Corp Takes $4.68 Million Position in Waters Corporation $WAT

FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteran

LabiotechEight oncology deals in 2026 spotlight where industry leaders are betting big

Endpoints NewsFulcrum lays off majority of staff; Seres extends runway into 2027

PharmaVoiceGSK, Takeda and others notch key clinical wins in tough-to-treat diseases

FierceBiotechHow RA Capital is offering its biotechs ‘Chinese clinical expertise in a box’

Endpoints NewsNovo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec

BioPharma DivePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter

CellSingle-cell mapping of regulatory DNA-protein interactions

CellPlasma signals of lung tumor promotion for molecular cancer prevention

CellDeep learning of functional perturbations from condensate morphology

FierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts